Golden rules for registrars
Medico-legal adviser Dr Jim Rodger offers some expert advice on how to excel as a GP registrar. Read more
The study showed RA patients taking the tumour necrosis factor (TNF)-alpha blocker infliximab had an increased atherogenic index and higher level of total cholesterol a year after treatment was initiated.
TNF-alpha blockers may add to the increased cardiovascular risk RA patients are known to have. Cardiovascular disease is more common in RA patients than the general population.
Under NICE guidance, RA patients are offered infliximab or the TNF-alpha blocker etanercept in combination with methotrexate if they have failed to respond to two other disease modifying anti-rheumatic drugs including methotrexate.
For the study, plasma lipoprotein concentrations were assessed in 55 RA patients and 55 controls, showing no differences between the groups' lipid profiles.
RA patients had a disease activity score above 3.2 and were starting therapy with infliximab.
At one year, 31 RA patients were reassessed for lipid profile. HDL cholesterol levels were similar to those at baseline and the atherogenic index was 4 per cent higher than baseline. Total cholesterol had increased from 5.55 mmol/l to 6.01 mmol/l.
Arch Rheum Dis 2007 Online
What do you think? Comment below or email us at healthcare.republic@haymarket.com
Quick search - use * for an abbreviated search, eg nico*
Medico-legal adviser Dr Jim Rodger offers some expert advice on how to excel as a GP registrar. Read more
Dr Kingsley Poole describes the differences he experienced working at a remote practice in New Zeala... Read more
Most people feel nervous facing an audience, but practice will make it easier, says Dr Kevin Brown. Read more
Contributed by Dr Charlie Easmon specialist adviser in travel medicine and medical director at The N... Read more
Contributed by Mr Ranan DasGupta, specialist registrar and Mr Jonathon Olsburgh, consultant urologic... Read more
By Dr Helen Hosker, GP and clinical commissioning lead for stroke, NHS Manchester, and Dr Pippa Tyrr... Read more
Leo Pharma has launched Xamiol gel, a combination of calcipotriol + betamethasone, for the treatment... Read more
Bayer HealthCare has launched Xarelto (rivaroxaban) for the prevention of venous thromboembolism in ... Read more
Wyeth has launched Torisel (temsirolimus), a first-line treatment for advanced renal cell carcinoma ... Read more
Comments
Only registered users may comment. Log in now or register for a free account.